Pulmonary Function Testing (PFT) is a fundamental tool in diagnosing and managing patients with respiratory disorders. Despite its importance, many healthcare professionals find PFT interpretation challenging. This article aims to provide a comprehensive guide to understanding and interpreting PFT results.
The key components of PFT include spirometry, lung volume measurements, and diffusion capacity. Spirometry assesses the airflow and volume of the lungs, providing values such as Forced Vital Capacity (FVC) and Forced Expiratory Volume in one second (FEV1). Lung volume measurements, including Total Lung Capacity (TLC), provide insights into restrictive lung diseases. The diffusion capacity measures how well oxygen moves from the lungs to the bloodstream.
Spirometry readings primarily indicate obstructive or restrictive lung diseases. An FEV1/FVC ratio less than 0.7 suggests obstructive disease. A reduced FVC with a normal or increased FEV1/FVC ratio suggests restrictive disease. However, these are general guidelines and clinical correlation is essential.
Reduced TLC indicates restrictive lung disease. An increased Residual Volume (RV) may suggest air trapping, common in obstructive diseases. A low Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) may suggest interstitial lung disease or pulmonary vascular disease, but can also be reduced in emphysema.
While PFT provides valuable information, its interpretation should always be correlated with the patient's clinical picture. Symptoms, physical examination findings, and other investigations should be considered to make an accurate diagnosis.
Interpreting PFTs can be complex, but understanding the individual components and their implications can improve diagnostic accuracy and patient care. It is essential to integrate PFT results with the overall clinical context to make meaningful interpretations.
1.
Trial Supports Ivonescimab and Chemo for NSCLC Survival
2.
Cancer "Tidal Wave" Prediction: Not Cigarette-Based, Either! Wary Stories Regarding Cannabis and Cancer.
3.
Lymph node transfer reduces arm swelling after breast cancer surgery, study shows
4.
Silibinin is a novel and ancient molecule that highlights the significance of integrated therapies for cancer.
5.
Research Indicates that First-Line Immunotherapy Is Enough for Elderly NSCLC Patients?
1.
Unlocking the Power of Hematocrit: Exploring the Benefits of Blood Cell Counts
2.
Unpacking Chordoma: Understanding the Rare Cancer and its Treatment Options
3.
Colorectal Cancer Incidence Trends: A Growing Concern in 2024 and 2025
4.
Uncovering the Mysteries of the RDW Blood Test
5.
The Basics of Langerhans Cell Histiocytosis: Understanding a Rare Disease
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part II
2.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management
3.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
4.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
5.
Navigating the Complexities of Ph Negative ALL - Part XIV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation